Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.57 |
| ▸ | ITGAV | P06756 | 3/20 | 0.57 |
| ▸ | MC4R | P32245 | 5/20 | 0.51 |
| ▸ | MC5R | P33032 | 5/20 | 0.51 |
| ▸ | MC3R | P41968 | 5/20 | 0.51 |
| ▸ | MC1R | Q01726 | 5/20 | 0.51 |
| ▸ | CTSG | P08311 | 2/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.50 |
| ▸ | TSLP | Q969D9 | 6/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908265 | 0.94 | ITGB3 (0.63) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13870357 | 0.94 | ITGB3 (0.63) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13870347 | 0.94 | ITGB3 (0.63) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13014846 | 0.90 | ITGB3 (0.58) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL14090937 | 0.90 | ITGB3 (0.64) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL11933454 | 0.90 | ITGB3 (0.51) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL12353635 | 0.90 | ITGB3 (0.57) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL11928877 | 0.90 | ITGB3 (0.64) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13658001 | 0.89 | ITGB3 (0.60) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL16298655 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVMC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8241606-B2 | Synthesis of a radiofluorinated peptide using photolabile protecting groups | GE HEALTHCARE AS (NO) | 2012-08-14 | — | — | US | disclosed |
| US-20100022746-A1 | SYNTHESIS OF A RADIOFLUORINATED PEPTIDE USING PHOTOLABILE PROTECTING GROUPS | GE HEALTHCARE AS (NO) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022746-A1 | SYNTHESIS OF A RADIOFLUORINATED PEPTIDE USING PHOTOLABILE PROTECTING GROUPS | QRFPR, DNPEP, VIP | ITGB3 3556/4885ITGAV 3167/4885MC4R 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.